Company intelligence / Profile preview

Moat Biotechnology

Oklahoma City, Oklahoma, United Statesboydstreetventures.com ↗

Ownership: Private
Development stage: Other

Overview

The lead intranasal COVID‑19 vaccine candidate has demonstrated safety and tolerability in ascending dose cohorts in a Phase I trial and elicited strong mucosal and systemic neutralizing antibody responses as well as a Th1-skewed T cell response against the SARS-CoV‑2 spike protein when given as a boost to subjects previously vaccinated with mRNA vaccines. Preclinical data support broad application of the SC-AdVax platform to multiple infectious diseases.

Therapeutic areas: Infectious Diseases
Modalities: VaccineAdenovirus-based vaccineBiologic
Industry: Biotech

Partnerships

Mayo Clinic (exclusive license for SC-AdVax platform)Cortado Ventures and Boyd Street Ventures are key investors/fundersTetherex Pharmaceuticals Corp. was parent/spinoff originator

Beyond the preview

Go deeper on Moat Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moat Biotechnology.

Explore the full profile